Authors:
Serretti, A
Zanardi, R
Rossini, D
Cusin, C
Lilli, R
Smeraldi, E
Citation: A. Serretti et al., Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity, MOL PSYCHI, 6(5), 2001, pp. 586-592
Authors:
Perez, J
Tardito, D
Racagni, G
Smeraldi, E
Zanardi, R
Citation: J. Perez et al., Protein kinase A and Rap1 levels in platelets of untreated patients with major depression, MOL PSYCHI, 6(1), 2001, pp. 44-49
Authors:
Zanardi, R
Artigas, F
Moresco, R
Colombo, C
Messa, C
Gobbo, C
Smeraldi, E
Fazio, F
Citation: R. Zanardi et al., Increased 5-hydroxytryptamine-2 receptor binding in the frontal cortex of depressed patients responding to paroxetine treatment: A positron emission tomography scan study, J CL PSYCH, 21(1), 2001, pp. 53-58
Authors:
Zanardi, R
Serretti, A
Rossini, D
Franchini, L
Cusin, C
Lattuada, E
Dotoli, D
Smeraldi, E
Citation: R. Zanardi et al., Factors affecting fluvoxamine antidepressant activity: Influence of pindolol and 5-HTTLPR in delusional and nondelusional depression, BIOL PSYCHI, 50(5), 2001, pp. 323-330
Authors:
Perez, J
Tardito, D
Mori, S
Racagni, G
Smeraldi, E
Zanardi, R
Citation: J. Perez et al., Abnormalities of cAMP signaling in affective disorders: implications for pathophysiology and treatment, BIPOL DIS, 2(1), 2000, pp. 27-36
Authors:
Zanardi, R
Benedetti, F
Di Bella, D
Catalano, M
Smeraldi, E
Citation: R. Zanardi et al., Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene, J CL PSYCH, 20(1), 2000, pp. 105-107
Authors:
Franchini, L
Rossini, D
Bongiorno, F
Spagnolo, C
Smeraldi, E
Zanardi, R
Citation: L. Franchini et al., Will a second prophylactic treatment with a higher dosage of the same antidepressant either prevent or delay new depressive episodes?, PSYCHIAT R, 96(1), 2000, pp. 81-85
Authors:
Serretti, A
Lattuada, E
Zanardi, R
Franchini, L
Smeraldi, E
Citation: A. Serretti et al., Patterns of symptom improvement during antidepressant treatment of delusional depression, PSYCHIAT R, 94(2), 2000, pp. 185-190
Authors:
Franchini, L
Gasperini, M
Zanardi, R
Smeraldi, E
Citation: L. Franchini et al., Four-year follow-up study of sertraline and fluvoxamine in long-term treatment of unipolar subjects with high recurrence rate, J AFFECT D, 58(3), 2000, pp. 233-236
Authors:
Zanardi, R
Franchini, L
Serretti, A
Perez, J
Smeraldi, E
Citation: R. Zanardi et al., Venlafaxine versus fluvoxamine in the treatment of delusional depression: A pilot double-blind controlled study, J CLIN PSY, 61(1), 2000, pp. 26-29
Authors:
Perez, J
Tardito, D
Mori, S
Racagni, G
Smeraldi, E
Zanardi, R
Citation: J. Perez et al., Altered Rap1 endogenous phosphorylation and levels in platelets from patients with bipolar disorder, J PSYCH RES, 34(2), 2000, pp. 99-104
Authors:
Franchini, L
Zanardi, R
Gasperini, M
Smeraldi, E
Citation: L. Franchini et al., Two-year maintenance treatment with citalopram, 20 mg, in unipolar subjects with high recurrence rate, J CLIN PSY, 60(12), 1999, pp. 861-865
Authors:
Perez, J
Tardito, D
Mori, S
Racagni, G
Smeraldi, E
Zanardi, R
Citation: J. Perez et al., Abnormalities of cyclic adenosine monophosphate signaling in platelets from untreated patients with bipolar disorder, ARCH G PSYC, 56(3), 1999, pp. 248-253
Authors:
Zanardi, R
Franchini, L
Gasperini, M
Lucca, A
Smeraldi, E
Perez, J
Citation: R. Zanardi et al., Faster onset of action of fluvoxamine in combination with pindolol in the treatment of delusional depression: A controlled study, J CL PSYCH, 18(6), 1998, pp. 441-446